

Evaluating TOUR006 in Participants with Chronic Kidney Disease and Elevated Hs-CRP: Rationale and Design of the TRANQUILITY Phase 2 Study

TOURMALINE

Emil deGoma¹, Yung Chung¹, Kristine Erickson¹, John Walsh¹, Ryan Larrobino¹, Michael D. Shapiro²

¹Tourmaline Bio, Inc., New York, NY, USA; ²Wake Forest University School of Medicine, Winston-Salem, NC, USA

BACKGROUND

- **Atherosclerotic cardiovascular disease (ASCVD)**, including coronary artery disease (CAD), large artery ischemic cerebrovascular disease, and peripheral artery disease (PAD), remains the leading cause of mortality globally.¹
- Once considered a mere consequence of cholesterol buildup, ASCVD is now recognized as an **inflammatory disorder** driven by chronic inflammation. Interleukins such as **IL-6** as well as other cellular constituents, orchestrate complex inflammatory responses that play pivotal roles in the disease's pathogenesis.²
- Human genetic studies have consistently shown associations between **genetic variants mimicking (low) dose IL-6 inhibition** and a **lower risk of ASCVD** (Figure 1).³⁻⁶
- Multiple studies have also demonstrated **associations between levels of IL-6 and C-reactive protein (CRP)**, a key biomarker for IL-6 pathway activity, and **ASCVD risk**.^{7,8}
- Recently, three large analyses of high-risk patient populations have shown that **high-sensitivity CRP (hs-CRP)** is more strongly associated with **risk of major adverse cardiovascular events (MACE)** than low-density lipoprotein cholesterol (LDL-C) (Figure 2).⁹⁻¹¹




Figure 1. IL-6 genetic variants are associated with hs-CRP levels and CVD risk. Specific genotypes at rs2228145 and rs7529229 are associated with lower hs-CRP levels and lower CHD risk (shown as hazard ratios). Figure was adapted from Ridker, 2016¹². CHD, coronary heart disease.




Figure 2. Risk of MACE and CV death across different LDL-C and hs-CRP levels. Analyses of multiple clinical trial populations demonstrated higher risk for MACE and CV death (shown as hazard ratios) for individuals with elevated hs-CRP.⁹⁻¹¹ MACE includes myocardial infarction, stroke, coronary revascularization, and CV death. CV, cardiovascular.

TOUR006

- **TOUR006** is a **long-acting, fully human, anti-IL-6 monoclonal antibody** with unique properties, including a naturally **long half-life**, **low immunogenicity**, and **high binding affinity to IL-6**.
- TOUR006 (formerly known as PF-04236921) has been previously studied in 448 participants, including patients with autoimmune disorders such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Crohn's disease (CD), across six completed Phase 1/2 trials.¹³⁻¹⁵
- Pharmacokinetic (PK) and pharmacodynamic (PD) modeling in virtual patient populations with systemic inflammation that is comparable to patients with ASCVD showed **significant reductions in hs-CRP** with both monthly and quarterly subcutaneous (SC) dosing of TOUR006 (Figures 3 & 4).¹³
- To date, the safety profile of TOUR006 has appeared **generally similar to other IL-6 pathway inhibitors**, and the highest planned Phase 2 dose (50 mg) did not show excess safety risk vs placebo in previous Phase 2 studies in CD and SLE.^{14, 15}
 - The most common AEs observed across all six completed Phase 1/2 studies included: headache, nasal congestion, oropharyngeal pain, abdominal pain, diarrhea, pain in extremity, arthralgia, nausea, fatigue, vomiting, and nasopharyngitis/upper respiratory infection.
- Currently, Tourmaline is developing TOUR006 for the treatment of **ASCVD** and **thyroid eye disease**, with additional diseases under consideration.




Figure 3. Median hs-CRP concentrations in completed studies of TOUR006 in patients with inflammatory disorders. Median hs-CRP levels over time are shown from four clinical studies in patients with RA, SLE, or CD. IV, intravenous; OLE, open-label extension.




Figure 4. Change in hs-CRP from PK/PD modeling. A PK/PD model developed using data from five studies in patients with RA, SLE, and CD, and healthy volunteers, demonstrated reductions in median hs-CRP (left), achievement of hs-CRP <2mg/L (center), and >50% reductions in hs-CRP (right) with TOUR006 dosed SC 50 mg quarterly, 25 mg quarterly, or 15 mg monthly.

TRANQUILITY STUDY

- **TRANQUILITY** is an ongoing Phase 2, randomized, double-blind, placebo-controlled, multicenter trial enrolling at ~40 sites located across the United States (Figure 5).
- **PURPOSE:** The Phase 2 TRANQUILITY Trial is designed to evaluate the safety, PK, PD, and hs-CRP lowering effect of quarterly and monthly subcutaneous administration of TOUR006 in ASCVD defined as patients with chronic kidney disease (CKD) and elevated hs-CRP.
 - The CKD population was chosen for this study due to the high prevalence of elevated hs-CRP and supporting evidence for IL-6 pathway activation leading to increased risk for ASCVD in patients with CKD.




Figure 5. TRANQUILITY study design overview. Approximately 120 patients with CKD stage 3 or 4 and hs-CRP \geq 2 and <15 mg/L are planned for enrollment. Patients will be stratified by CKD stage and randomized to receive SC TOUR006 50 mg quarterly, 25 mg quarterly, 15 mg monthly, or placebo for 6 months. Assessments will continue for 6 months following completion of treatment. eGFR, estimated glomerular filtration rate.

Table 1. Key outcome measures for the Phase 2 TRANQUILITY Study.

Primary Outcome Measures
• Change from baseline in hs-CRP after 90 days of treatment
Secondary Outcome Measures
• Change from baseline in hs-CRP after 180 days of treatment
• Serum drug concentrations of TOUR006 at baseline and after 30, 60, 90, 120, 150, and 180 days of treatment
• Serum drug concentrations of TOUR006 at 210, 240, 330, and 365 days
Safety Outcome Measures
• Proportion of participants with AEs, SAEs, severe AEs, and AEs leading to discontinuation
• Description and frequency of events of special interest by treatment group
• Description of additional safety assessments by treatment group and dose (e.g., vital signs, electrocardiogram, and anti-drug antibodies)
Exploratory Outcome Measures
• Change from baseline in serum amyloid A, lipoprotein (a), neutrophil-to-lymphocyte ratio, fibrinogen, oxidized low-density lipoprotein, plasminogen activator inhibitor-1, and IL-6

CONCLUSIONS

- As a fully human, anti-IL-6 monoclonal antibody, TOUR006 introduces a **novel approach** to targeting key inflammatory pathways implicated in the progression ASCVD.
- TOUR006 is being developed and investigated towards an aim of **addressing persistent cardiovascular risk** in patients despite lifestyle modification and existing pharmacologic interventions.
- TOUR006 is being evaluated in the ongoing TRANQUILITY study to characterize the safety and tolerability, PK, and hs-CRP-lowering effect of TOUR006, and to inform the dosing and design of future Phase 3 outcome studies in CV indications.

ACKNOWLEDGEMENTS

- Writing and editorial support was provided by Talisa Silzer, PhD and Holly Szczepanski, MSc of sixsense strategy group inc., Toronto, Ontario, Canada, and funded by Tourmaline Bio, Inc.

DISCLOSURES

- ED, YC, KE, JW, and RI are employees of Tourmaline Bio, Inc. MDS is a consultant for Tourmaline Bio, Inc.

MORE INFORMATION

- To **learn more**, please visit: <https://www.tourmalinebio.com/science/>
- For more information on the **Phase 2 TRANQUILITY Study** (NCT06362759), please visit: www.clinicaltrials.gov



REFERENCES:

1. WHO (2020).
2. Alfaddagh et al., *Am J Prev Cardiol* (2020).
3. Sarwar et al., *Lancet* (2012).
4. Swerdlow et al., *Lancet* (2012).
5. Cai et al., *JAMA Cardiol* (2018).
6. Levin et al., *Circ Res* (2021).
7. Kaptoge et al., *Eur Heart J* (2014).
8. Batra et al., *JAMA Cardiol* (2021).
9. Ridker et al., *Lancet* (2023).
10. Ridker et al., *Circulation* (2023).
11. Ridker et al., *Eur Heart J* (2022).
12. Ridker, *Circ Res* (2016).
13. Li et al., *Br J Clin Pharmacol* (2018).
14. Danese et al., *Gut* (2019).
15. Wallace et al., *Ann Rheum Dis* (2016).